8YY — Biolidics Cashflow Statement
0.000.00%
Last trade - 00:00
- SG$7.45m
- SG$8.57m
- SG$1.32m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.81 | -4.68 | -6.04 | -9.85 | -2.49 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.072 | 2.2 | 0.697 | 5.53 | 0.315 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.46 | -0.939 | -0.531 | 0.07 | -0.034 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -4.56 | -2.43 | -4.62 | -3.06 | -1.97 |
Capital Expenditures | -0.686 | -0.449 | -0.562 | -0.093 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.015 | -0.09 | -0.299 | 0.098 | -2.69 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.671 | -0.539 | -0.861 | 0.005 | -2.69 |
Financing Cash Flow Items | 0 | -0.028 | 0 | -0.223 | -0.058 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.258 | 7.5 | -1.16 | 4.18 | -0.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -5.47 | 4.64 | -6.71 | 1.07 | -4.85 |